Decode Age Secures $150K Seed Investment in Longevity Science

Decode Age, an India-based company focused on longevity, has raised $150,000 from investors to further its mission of redefining health. The company is dedicated to addressing ageing at a cellular level, aiming to extend human healthspan by confronting one of humanity’s greatest challenges. This funding round underscores growing investor confidence in Decode Age's pioneering approach to health and wellness. As India’s first longevity-focused company, Decode Age operates by merging cutting-edge science, biomarker testing, and evidence-based supplements into an integrated ecosystem. Its core philosophy is to move beyond treating the symptoms of chronic diseases by instead tackling their common root cause: ageing. A multidisciplinary team translates breakthrough scientific research into personalized longevity solutions. Decode Age’s offerings include gut microbiome tests and a curated portfolio of advanced nutraceuticals designed to help individuals track, improve, and optimize their age. This investment highlights the increasing interest in the longevity sector and Decode Age’s comprehensive strategy to provide tools for better health. The capital infusion will be strategically utilized to accelerate Decode Age's research and development initiatives, enabling further innovation in its product offerings. The funds will also support the expansion of its integrated ecosystem and enhance its market penetration, allowing more individuals to access its personalized longevity solutions. This investment is expected to bolster Decode Age's efforts to scale operations and strengthen its position within India's emerging longevity market. Looking ahead, Decode Age is focused on expanding its reach and deepening its scientific research to continue empowering people to achieve a longer, healthier life. The company aims to cultivate a new way of thinking about health and potential, building on its foundation to redefine the future of well-being.